Early discharge strategies following venous thrombosis

Abstract

Low-molecular-weight heparin therapy is administered subcutaneously, not intravenously. This has made possible the management of selected patients who have acute deep venous thrombosis as outpatients. Others can be treated with an abbreviated several day hospitalization rather than the conventional 5 or more hospital days needed for administration of continuous intravenous unfractionated heparin. Two large studies, Tasman and a Canadian trial, have demonstrated the efficacy and safety of low-molecular-weight heparin in this setting. Now, the task is to develop guidelines for widespread application of these findings to daily clinical practice. However, successful home treatment will require intensive patient education as well as an extensive infrastructure of supportive nursing and physician services. Careful patient follow-up will be crucially important.

Keywords

anticoagulation deep venous thrombosis low-molecular-weight heparin out-patient therapy pulmonary embolism venous thromboembolism

References

Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996; 335: 1816-1828.

Brandjes DPM , Heijboer H , Büller HR et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327: 1485-1489.

Gallus A , Jackaman J , Tillet J et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986; ii: 1293-1296.

Hull RD , Raskob GE , Rosenbloom D et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal-vein thrombosis. N Engl J Med 1990; 322: 1260-1266.

Hommes DW , Bura A , Mazzolai L et al. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Intern Med 1992; 116: 279-284.

Leape LJ , Brennan TA , Laird NM et al. The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study II. N Engl J Med 1991; 324: 377-384.

Hirsh J , Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.

Young E , Prins MH , Levine MN , Hirsh J. Heparin binding to plasma proteins. An important mechanism for heparin resistance. Thromb Haemost 1992; 67: 639-643.

Kuijer PMM , Prins MH , Büller HR. Low-molecular-weight heparins: treatment of venous thromboembolism. In: Sasahara AA , Loscalzo J eds. Advances in therapeutic agents in thrombosis and thrombolysis. New York: M Dekker Inc., 1997: 129-147.

10.

The Columbus Investigators . Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657-662.

11.

Simonneau G , Sors H , Charbonnier B et al , on behalf of the THÉSEE Study Group . A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337: 663-669.

12.

Levine MN , Gent M , Hirsh J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996; 334: 677-681.

13.

Koopman MMW , Prandoni P , Piovella F et al , on behalf of the TASMAN-study group . Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682-687.

14.

Lensing AWA , Prins MH , Davidson BL , Hirsh J. Treatment of deep vein thrombosis with low molecular weight heparins, a meta-analysis. Arch Intern Med 1995; 155: 601-607.

15.

van den Belt AGM , Bossuyt PMM , Prins MH , Gallus AS , Büller HR , on behalf of the Tasman Study Group . Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis. A cost-minimisation analysis. Thromb Haemost 1998; 79: 259-263.

16.

Wells PS , Kovacs MJ , Forgie MA , Bormanis J , Goudie D , Morrow B , Kovacs J. Outpatient treatment of deep venous thrombosis (DVT) with low molecular weight heparin. Blood 1996; 88(10 suppl 1): 659-659 (abstract).

17.

Heijboer H , Brandjes DPM , Büller HR , Sturk A , ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in out-patients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-1516.

18.

Prandoni P , Lensing AWA , Büller HR et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128-1133.